Whitney Economics (WE), a global leader in cannabis and hemp business consulting, data and economic research, today announced the release of its US cannabis revenue forecast for the period 2025 – 2030.

“We forecast legal revenue to reach $30.5 billion by 2026, a 4.9% increase from 2025,” said WE Founder and Chief Economist Beau Whitney. “This is a welcome change from just one year ago, when the US legal cannabis market experienced its first year-over-year revenue decline in the history of the legalized market.”

That decline, Whitney said, would have been worse nationally had it not been for strong growth in New York and Ohio, where consumers gained greater retail access to cannabis products. Although unit volumes and legal share rates remained strong, supply saturation resulted in price compression and reduced overall revenue in the U.S. “Growth rates are still positive, not as much as in previous years, when we forecast 13.4% growth by 2026,” he said.

In addition, price deflation has again reduced near- and medium-term sales expectations, with forecasts for 2026 and 2027 down from last year. “Whitney Economics’ forecast accuracy has always been in the mid-to-high 90% range, so when it dropped to 85% in 2025, we knew we had to update our models,” Whitney said. “Accounting for price compression was a major part of this adjustment.”

In the past, the key driver for predicting cannabis retail revenue was spending multiplied by the number of consumers. However, with price compression becoming a major factor in the US cannabis market, forecasts must account for market deflation, and WE has updated its model to include price declines.

Whitney’s prediction is that cannabis consumer behavior has changed significantly since the end of the Covid-19 era, with consumers spending essentially the same amount each month. Cannabis spending patterns underwent a major shift in 2023 and 2024, with cannabis spending now beginning to reflect broader consumption patterns.

“In times of uncertainty and higher inflation, consumers are no longer adding to their carts; instead, they are buying only what they need and saving on other cannabis-related purchases,” Whitney said. “As a result of this change, for the first time, price compression has become a major variable in the cannabis forecast equation.”

Since 2014, when Washington and Colorado states rolled out the first state-based adult cannabis regulation programs, the growth of individual markets, fueled by an influx of legal consumers, has overshadowed any price compression taking place. Market growth outpaced the impact of price declines. However, as markets began to mature and the pace of consumer conversion to the legal market slowed, price compression had a greater impact on market growth.

“We’re approaching the point where the growth rates of legal share are slowing while price declines have accelerated,” Whitney said. “Consequently, price compression will play an important role in advancing market value. This is a sign of market maturity.”

With the level of price compression and its suppressive effect on market growth, states must factor this into their tax revenue projections, which are expected to decline. States can no longer expect to raise taxes to make up for lost revenue because those increases will reduce demand, just like in any other industry, Whitney said.

Despite the importance of price compression, US cannabis revenue projections still point to growth for the remainder of the decade. But given the falling prices, legislators and regulators will be forced to encourage consumers to participate in the legal market; otherwise, retail and tax revenues will continue to decline.

“Perhaps this will lead to a move away from the marijuana dispensary model and opening up sales through other distribution channels, such as grocery stores and big box retailers,” Whitney said. “The US market is at a crossroads where the market is normalizing and no longer experiencing exponential growth. Single-digit growth will become the norm moving forward.”

The Yale Center for the Science of Cannabis and Cannabinoids (YC-SCAN²) announced on March 11 a new collaboration with the McGill Research Center for Cannabis (MRCC), taking an important step in strengthening international collaborations in cannabis and cannabinoid research.

As part of this partnership, MRCC will sponsor and help promote YC-SCAN²’s monthly educational webinar series. The webinars feature talks from leading researchers and clinicians who explore the science of cannabis and cannabinoids from a variety of perspectives. Open to the public, the series creates a platform where experts can present emerging findings, discuss key scientific questions, and engage researchers, clinicians, students, and the wider academic community.

The partnership reflects a shared commitment to advancing rigorous evidence-based research in a rapidly evolving field. By connecting researchers from different institutions and disciplines, the two centers aim to accelerate scientific discovery while promoting the exchange of knowledge across borders.

Deepak C. D’Souza, MD, the Vikram Sodhi ’92 Professor of Psychiatry and director of YC-SCAN², said the collaboration builds on a longstanding professional relationship with colleagues at McGill.

“Romina (Mizrahi, director of the MRCC) and I have shared a long-standing interest in advancing rigorous research on cannabis and cannabinoids, and have collaborated for several years to achieve this goal,” he said. “This collaboration between Yale and McGill reflects the importance of bringing together researchers across institutions to exchange ideas, support trainees, and accelerate scientific progress in this rapidly evolving field.”

Mizrahi emphasized the opportunities the partnership creates for future collaboration and training.

“I’m excited about this new chapter for our centers,” he said. “This partnership brings together complementary expertise and creates new opportunities for joint training, knowledge exchange and collaborative research excellence. By working together, we can strengthen the scientific foundation across the full spectrum of cannabis research, from plant science to understanding the effects of cannabis on the body, brain and society.”

Going forward, both centers plan to expand the webinar initiative with virtual “Lunch and Learn” sessions specifically designed for interns and junior researchers. These sessions will provide opportunities for early career researchers to present their work, network with peers and learn from top scientists in the field. The programming will focus on mentoring, interdisciplinary learning and strengthening skills in communicating scientific findings.

The partnership reflects YC-SCAN²’s broader goal of developing long-term partnerships with organizations that share a mission to advance cannabis science. By building networks between universities and research centers, the initiative aims to support high-quality research, promote innovation and help translate scientific findings into informed public policies.

Founded in 2023, YC-SCAN² works to advance the understanding of cannabis and its derivatives, commonly known as cannabinoids. The center serves as a center for research, education and dissemination of information in the field. His work explores the potential therapeutic applications and risks associated with cannabis and cannabinoids, while helping to inform public policy through evidence-based research.

Source: Yale School of Medicine

A new Senate bill is being introduced that would encourage research into the therapeutic potential of psychedelics, create a new office at the Department of Veterans Affairs (VA) to develop innovative treatments for serious mental health illnesses, and help review the scheduling status of drugs like psilocybin, ibogaine and MDMA.

The legislation, titled the “Veterans Health Administration New Therapeutics Training Act,” is sponsored by Senator Tim Sheehy (R-MT). According to bill text obtained by Marijuana Moment, it would direct the VA to take steps to ease studies on psychedelics and other emerging therapies.

This is one of the latest examples of Congressional efforts to encourage scientific research on psychedelics, focusing on military veterans with conditions such as post-traumatic stress disorder (PTSD), treatment-resistant depression, substance use disorder, traumatic brain injury (TBI), chronic pain, and more.

The bill is expected to be formally introduced on Wednesday, according to a source familiar with the planning. Marijuana Moment reached out to Sheehy’s office for comment, but a representative was not immediately available.

“Ongoing therapeutic interventions, including some psychedelic-assisted therapies, that have been evaluated by the Food and Drug Administration since the enactment of this Act could significantly change the landscape of treatment for post-traumatic stress disorder, depression, and other mental health conditions affecting veterans,” the bill finds.

“The administration of certain emerging therapies may require intensive clinical engagement, interdisciplinary teams, dedicated clinical space, structured preparation and post-treatment integration that differ significantly from traditional outpatient mental health services,” he continues, adding that the VA is “uniquely positioned to provide comprehensive veteran-centered care that combines mental health, medical health services and support into a single system.”

That’s the only explicit mention of “psychedelics” in the legislation, and it doesn’t list the specific psychedelic substances that would be prioritized for research, but that’s a common feature of recent bills on the subject, with many other examples using catchy terminology, such as innovative or novel treatments or therapies that effectively serve as “substitutes for psychedelics.”

The measure would establish a new Office of New Therapeutics under the Veterans Health Administration (VHA) to facilitate research initiatives. Studies examining alternative treatments would focus on substances such as psychedelics that are being considered for approval by the Food and Drug Administration (FDA).

“In the absence of centralized governance and implementation planning, the Department may experience delays, safety risks, or inconsistent access following regulatory approval of these therapies,” the bill’s findings section says. “Establishing a dedicated Office of New Therapeutics will enable the Department to proactively evaluate, research and implement emerging treatment modalities consistent with patient safety and evidence-based practice.”

There would be at least one “Center of Excellence” in each VA regional district to help develop a national model for the program facilitation initiative. A Veterans Advisory Board, made up of veterans, experts and health professionals, would be created to advise on issues such as access barriers and safety protocols.

VA should also coordinate with other federal agencies—including the US Department of Health and Human Services (HHS), FDA, Centers for Medicaid and Medicare Services (CMS), Department of Defense (DOD), and Drug Enforcement Administration (DEA)—to explore regulatory issues, possible rescheduling action for new therapies, and resources to provide psychiatric health care access and treatment.

The VA should provide annual reports to Congress to update lawmakers on its progress. Within 180 days of the bill’s passage, the department would have to report on practical issues, such as staffing needs and regulatory hurdles.

The bill is somewhat Similar intent to another bipartisan measure introduced earlier this monthSponsored by Senators Ruben Gallego (D-AZ) and David McCormick (R-PA), it would provide $30 million in annual funding to establish psychedelic-focused “centers of excellence” at VA facilities where veterans can receive innovative treatments involving substances such as psilocybin, MDMA and ibogaine.

Supplemental version of the house bill—Sponsored by the Chair of the Congressional Psychedelics Advancing Therapies (PATH) Caucus Reps. Lou Correa (D-CA) and Jack Bergman (R-MI)—were introduced last year, but have yet to advance in the House. The measures of the House and Senate are very similar, with minor format differences.

Lawmakers and advocates supporting those reform bills have allies in senior Trump administration positions, including VA Secretary Doug Collins and Robert F. Kennedy, Jr. Secretary of HHS, both of whom have endorsed psychedelic policy reform.

Kennedy recently told Joe Rogan on a podcast episode The administration is “very keen” to create a pathway for novel therapies and that federal agency officials want to “get the public up to speed as quickly as possible.”

Multiple veterans groups also recently advised lawmakers in Congress about the need continue to explore psychedelics and marijuana as alternative treatments At hearings on Capitol Hill for the military veteran population. The Wounded Warrior Project (WWP) and Veterans of Foreign Wars (VFW) specifically cited the Innovative Therapy Centers of Excellence Act as an example of a reform they are supporting.

Correa and Bergman, the sponsors of this legislation, submitted separately in January also to promote research into the therapeutic potential of certain psychedelics in the treatment of serious mental health conditions experienced by veterans.

January’s bipartisan pair also discussed it the importance of strategically advancing psychedelic reform in a way that mitigates bureaucratic conflict and the influence of external interests. They said even a single mistake could threaten to turn the movement upside down.

Last year, VA Secretary He proclaimed his mission to promote access to psychedelics for veterans with serious mental health conditions, it was possible to say that it “opened that door wider than most probably thought”. The department came under fire in 2024 after rejecting an organization’s grant application It helps connect veterans to programs overseas where they can receive psychedelic therapy to treat serious mental health conditions.

Meanwhile, in November, Kennedy, Vice President JD Vance, FDA Commissioner and other Trump administration officials attended the “Make America Healthy Again” summit. it was a session dedicated to studying psychedelic medicine.

In June, Kennedy said that his agency “Fully committed” to expanding research into the benefits of psychedelic therapy. and, along with the head of the FDA, aims to give military veterans legal access to these substances “within 12 months.”

The secretary also said that in April He had a “wonderful experience” with LSD at the age of 15He took it because he thought they would be able to see dinosaurs, as depicted in a comic he was a fan of.

Last October, Kennedy specifically criticized the FDA under the previous administration for the agency’s “eradication of psychedelics” and a laundry list of other issues that he said was a “war on public health” that would end under the Trump administration.

read it the text Under the Veterans Health Administration’s New Therapeutics Training Act: